These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38780912)

  • 1. Successful therapy of refractory cutaneous morphea with tofacitinib.
    Russo G; Dumont S; Laffitte E
    Ital J Dermatol Venerol; 2024 Aug; 159(4):469-470. PubMed ID: 38780912
    [No Abstract]   [Full Text] [Related]  

  • 2. Full histological and clinical regression of morphea with tofacitinib.
    Scheinberg M; Sabbagh C; Ferreira S; Michalany N
    Clin Rheumatol; 2020 Sep; 39(9):2827-2828. PubMed ID: 32424655
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience.
    Colussi L; Dagri A; Pastore S; Tommasini A; Pin A; Taddio A
    Int J Rheum Dis; 2024 Aug; 27(8):e15295. PubMed ID: 39164118
    [No Abstract]   [Full Text] [Related]  

  • 4. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.
    Komai T; Shoda H; Hanata N; Fujio K
    Scand J Rheumatol; 2018 Nov; 47(6):505-506. PubMed ID: 29260607
    [No Abstract]   [Full Text] [Related]  

  • 5. A pilot study of tofacitinib for refractory Behçet's syndrome.
    Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
    Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
    Liu S; Li C; Tang MW; Xu WS; Chen KQ; Sui X; Tian XL; Xu KF
    Chin Med J (Engl); 2019 Oct; 132(19):2378-2379. PubMed ID: 31503058
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.
    Kuwabara S; Tanimura S; Matsumoto S; Nakamura H; Horita T
    Ann Rheum Dis; 2020 Aug; 79(8):1125-1126. PubMed ID: 32213500
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Treatment of Paediatric Morphea with Tofacitinib.
    Tang JC; Zheng WY; Han GM; Liu SF; Yang B
    Acta Derm Venereol; 2023 Apr; 103():adv4805. PubMed ID: 37083093
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 10. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
    Haynes D; Topham C; Hagstrom E; Greiling T
    Australas J Dermatol; 2020 Feb; 61(1):e108-e110. PubMed ID: 31318041
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
    Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
    Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
    [No Abstract]   [Full Text] [Related]  

  • 12. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
    Bilori B; Thota S; Clemente MJ; Patel B; Jerez A; Afable Ii M; Maciejewski JP
    Leukemia; 2015 Dec; 29(12):2427-9. PubMed ID: 26449659
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
    Gregory MH; Ciorba MA; Deepak P; Christophi GP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 15. Alopecia universalis. Partial response to tofacitinib.
    Ruiz-Villaverde R; Cuenca-Barrales C; Linares-Gonzalez L; Ródenas-Herranz T
    Med Clin (Barc); 2019 Aug; 153(3):e15. PubMed ID: 30718001
    [No Abstract]   [Full Text] [Related]  

  • 16. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for familial Mediterranean fever: a new alternative therapy?
    Garcia-Robledo JE; Aragón CC; Nieto-Aristizabal I; Posso-Osorio I; Cañas CA; Tobón GJ
    Rheumatology (Oxford); 2019 Mar; 58(3):553-554. PubMed ID: 30535114
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
    Moghadam-Kia S; Charlton D; Aggarwal R; Oddis CV
    Rheumatology (Oxford); 2019 Jun; 58(6):1011-1015. PubMed ID: 30608616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.